Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer

Posted on by

TAIPEI, Sept. 27, 2024 /PRNewswire/ — Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen’s HDAC inhibitor, ABT-301, with BeiGene’s anti-PD-1 antibody tislelizumab, in patients with mismatch repair–proficient…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.